Prescient Therapeutics Hits Enrolment Threshold for PTX-100 Phase 2a Trial Review
Prescient Therapeutics hits enrolment milestone: PTX-100 Phase 2a reaches 20 evaluable patients; first Dose Optimisation...
Prescient Therapeutics hits enrolment milestone: PTX-100 Phase 2a reaches 20 evaluable patients; first Dose Optimisation...
ASX healthcare companies are increasingly looking to tap into licensing and partnering deals to fund...
Prescient advances PTX-100 in Phase 2a for CTCL; DOC review set for Dec 2026 as...
As cancer rates around the world climb for a range of reasons, one of the...
Host Tylah Tully sits down with Prescient Therapeutics (ASX:PTX) CEO James McDonnell to discuss the...
To walk us through the process, Tylah Tully is joined by Prescient Therapeutics (ASX:PTX) CEO,...
Small Caps speaks with Prescient Therapeutics (ASX: PTX) for a general company update focused on...
Special Report: Prescient Therapeutics has entered an important stage in development of its lead cancer...
Special Report: Clinical-stage oncology company Prescient Therapeutics has reached a key milestone in the Phase 2a...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.